Clinical Trial Update: Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating palbociclib with either letrozole or fulvestrant in estrogen receptor-positive, HER2-negative metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Letrozole (letrozole)
• Palbociclib (palbociclib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative | Phase 2 | Status: UNKNOWN | Results posted: 2021-10-15